We would love to hear your thoughts about our site and services, please take our survey here.
AZD7442 is a combination of two monoclonal antibodies and is being developed for the development and treatment of Covid-19. These antibodies are derived from convalescent patients infected with SARS-CoV-2 and were discovered by Vanderbilt University Medical Center and licensed to AstraZeneca in June.
Astra then optimised the antibodies, extending their half-life so as to "afford at least six months of protection from Covid-19".
If AZD7442 proves to be tolerated and has a "favourable safety profile" in the NCT04507256 trial then Astra will move to larger late-stage phase 2 and phase 3 trials. These later trials will evaluate AZD7442's efficacy as a possible preventative and treatment approach against the virus.
The trial will include as many as 48 healthy participants in the UK aged between 18 and 55. It is funded by the Defense Advanced Research Projects Agency, part of the US US Department of Defense, as well as the Biomedical Advanced Research and Development Authority. BARDA is part of the Office of the Assistant Secretary for Preparedness & Response at the US Department of Health & Human Services.
Mene Pangalos, executive vice president of BioPharmaceuticals Research & Development, said: "This trial is an important milestone in the development of our monoclonal antibody combination to prevent or treat Covid-19. This combination of antibodies, coupled to our proprietary half-life extension technology, has the potential to improve both the effectiveness and durability of use in addition to reducing the likelihood of viral resistance."
Alongside the antibody treatment, Astra is also developing a vaccine for Covid-19 with the University of Oxford. This vaccine would aim to prevent Covid-19 infection. In July, interim results from an ongoing phase 1/2 trial of vaccine AZD1222 were published showing it to be tolerated and able to generate robust immune responses against the virus in all evaluated participants. Phase 2/3 trials are ongoing with late-stage trial results expected later in 2020.
AstraZeneca (NYSE:AZN) has initiated a Phase 1 clinical trial of AZD7442, a combination of two monoclonal antibodies(mAbs) in development for the prevention and treatment of COVID-19.
The trial, which will include up to 48 healthy participants in the UK aged 18 to 55 years, will evaluate the safety, tolerability and pharmacokinetics of AZD7442. Data readout is anticipated in H2.
The U.S. Department of Defense and the Biomedical Advanced Research and Development Authority are providing funding for the trial.
Should AZD7442 achieve favorable results, AstraZeneca will move the treatment into late-stage Phase 2 and Phase 3 trials.
https://uk.reuters.com/article/us-health-coronavirus-astrazeneca-treatm/astrazeneca-starts-trial-of-covid-19-antibody-treatment-idUKKBN25L0KQ
(Reuters) - British drugmaker AstraZeneca has begun testing an antibody-based ****tail for the prevention and treatment of COVID-19, adding to recent signs of progress on possible medical solutions to the disease caused by the novel coronavirus.
The European Commission (EC) has reached an agreement with AstraZeneca (NYSE:AZN) to purchase up to 400M doses of COVID-19 vaccine AZD1222, if approved.
The EU has allocated €2B ($2.3B) to procure vaccines from up to six producers.
If you want to understand the different types of Covid-19 vaccines, and who is developing them and what stage of development they are at, the read this article in the Washington Post.
They let you read a few articles each month without taking out a subscription.
This is the reference:
https://www.washingtonpost.com/graphics/2020/health/covid-vaccine-update-coronavirus/?hpid=hp_hp-banner-main_vaccines-845am%3Ahomepage%2Fstory-ans&itid=hp_hp-banner-main_vaccines-845am%3Ahomepage%2Fstory-ans
AstraZeneca set to start making 400 million COVID-19 vaccines for Latam early in 2021
https://uk.reuters.com/article/uk-health-coronavirus-latam-vaccine/astrazeneca-set-to-start-making-400-million-covid-19-vaccines-for-latam-early-in-2021-idUKKCN2592N3
AstraZeneca (NYSE:AZN) has shipped the first lot of Flumist Quadrivalent (Influenza Vaccine Live, Intranasal) to the U.S. for the 2020-2021 flu season. It is indicated for people between the ages of 2 and 49, although it may not prevent influenza in everyone who gets vaccinated.
https://www.nature.com/articles/s41586-020-2550-z
Exec summary:
COVID-19 has weakened the US economy more than China's.
New research published in the journal Nature may partly explain the much lesser burden placed on China by COVID-19:
Long-lasting T cell immunity stimulated by prior exposure to the virus that caused SARS in 2003 (source: Le Bert et al., Singapore).
Not only was the US less prepared strategically for this virus to arrive, its populace may have been less prepared biologically.
Absent natural immunity via prior coronavirus exposure, vaccines that result in long-lasting T cell immunity are in the interest of national security.
I do not understand you last sentence/paragraph.nor do I know of what vaccine damage to which you are referring.
My view is that if any country doesn't want the vaccine then it can wait and the population will have to take their chances.
I will have it when it/they become available in the UK, yearly if necessary, as I do with flu vaccination.
My view is that AZN's position of asking for immunity is entirely reasonable.
Essentially it boils down to saying to sovereign countries that they have a choice. They can have the vaccine now but without all the usual safety checks or they can wait for 3 - 5 years until they are all done.
Note that in saying this does not mean that they are trying to knowingly foist and unsafe product onto the market; but they have to be cognisant of the way BP and Bayer have been treated by the US legal system.
Part 2
In the ELEVATE TN trial, Calquence combined with obinutuzumab reduced the risk of disease progression or death by 90% and 80% respectively, compared to standard chemo-immunotherapy treatment chlorambucil plus obinutuzumab in patients with previously untreated CLL. In the ASCEND trial, 88% of patients with relapsed or refractory CLL taking Calquence remained alive and free from disease progression after 12 months compared to 68% of patients on rituximab combined with idelalisib or bendamustine.
"With its outstanding efficacy and tolerability profile, Calquence can offer important advantages to patients with chronic lymphocytic leukaemia who are typically older, facing multiple comorbidities and often require treatment for many years. This positive recommendation brings us closer to providing a much-needed new treatment option to patients in Europe who are suffering from this chronic blood cancer," said Jose Baselga, executive vice president, Oncology research & development.
AstraZeneca PLC on Monday said it has entered into an oncology collaboration worth up to GBP6 billion with Daiichi Sankyo Co Ltd, as Astra also announced that Calquence and Imfinzi have been recommended for approval in the EU.
The FTSE 100 drug manufacturer said it has inked a global development and commercialisation agreement with Japanese peer Daiichi. The partnership will see both companies work on Daiichi Sankyo's proprietary trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate and potential new medicine for the treatment of multiple tumour types.
"DS-1062 is currently in development for the treatment of multiple tumours that commonly express the cell-surface glycoprotein TROP2. Among them, TROP2 is overexpressed in the majority of non-small cell lung cancers and breast cancers tumour types that have long been a strategic focus for AstraZeneca," the pharmaceutical firm said.
Astra and Daiichi will jointly develop and commercialise DS-1062 worldwide, except in Japan where Daiichi Sankyo will maintain exclusive rights.
AstraZeneca will pay Daiichi Sankyo USD1 billion upfront in staged payments, with USD350 million due on completion, USD325 million after a year and USD325 million after two years. AstraZeneca will pay additional conditional amounts of up to USD1 billion for the successful achievement of regulatory approvals and up to USD4 billion for sales-related milestones.
"We see significant potential in this antibody drug conjugate in lung as well as in breast and other cancers that commonly express TROP2. We are delighted to enter this new collaboration with Daiichi Sankyo and to build on the successful launch of Enhertu to further expand our pipeline and leadership in Oncology," said AstraZeneca Chief Executive Pascal Soriot.
Separately, Astra said its Imfinzi drug has been recommended for marketing authorisation in the EU for the first-line treatment of adults with extensive-stage small cell lung cancer.
It said the recommendation by the Committee for Medicinal Products for Human Use of the European Medicines Agency was based on results from the Phase III CASPIAN trial for Imfinzi plus chemotherapy which showed that the combined treatments reduced the risk of death by 27% compared with chemotherapy alone. Results also demonstrated that Imfinzi added to chemotherapy delayed the time it took for lung cancer-related symptoms to worsen.
Another Astra drug, Calquence, has been recommended for approval in the EU for the treatment of adult patients with chronic lymphocytic leukaemia. The positive opinion by the committee was based on results from two Phase III clinical trials, ELEVATE TN in patients with previously untreated CLL, and ASCEND in patients with relapsed or refractory CLL.
In the ELEVATE TN trial, Calquence combined with obinutuzumab reduced the risk of disease progression or death by 90% and 80% respectively, compared to standard chemo-immunotherapy treatment chlorambucil plus obinut
Oxford vaccine produces "double defence" against SARS-CoV-2
Jul. 15, 2020 4:59 PM ET|About: AstraZeneca PLC (AZN)|By: Douglas W. House, SA News Editor
London's Telegraph reports that results from a Phase 1 clinical trial evaluating Oxford University's COVID-19 vaccine candidate ChAdOx1 nCoV-19 [ADZ1222 by licensee AstraZeneca (NYSE:AZN)] in healthy volunteers showed that it triggered a "double defense" immune response against the SARS-CoV-2 virus.
Researchers noted that administration of the candidate produced both antibodies and killer T cells. The response, if confirmed, has significant implications for sustained immunity since antibodies may fade away within months while T cells remain in circulation for years.
Chet.theden posts:So put £400 into amazon and £300 in Apple. and £300 in amd. Im obviously up , but up! but its not really life changing. He writes that he bought these at the beginning of lock down.
I am confused by this post. How is this possible?
In March Amazon were trading at about US$1800 / share. How do you put only £400into the stock?
Amazon BTW are now trading at $3200/ share and my dear wife holds 43 of them. Do the maths.
The confirmed cases are only the ones that were diagnosed by PCR testing. There are many more who had the disease but who are not counted in the confirmed cases count. I include my son (now recovered) in this category. Hr is a doctor. He had the symptoms and has subsequently been shown to have antibodies to Covid-19.
The deaths are a tragically real number.
Hence your death rate calculation is WRONG!
https://finance.yahoo.com/news/astrazeneca-covid-19-vaccine-likely-080522108.html